ReviewFrontiers in immunology2026
Respiratory epithelial cells as central mediators of immune crosstalk in SARS-CoV-2 infection.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces life-threatening acute lung injury (ALI) and disrupts immune homeostasis, however, the role of epithelial-immune cell crosstalk in driving this pathology remains incompletely elucidated. Respiratory epithelial cells (RECs) as the primary targets of SARS-CoV-2 via the ACE2 receptor, act as central mediators of immune crosstalk that balances antiviral defense and immunopathology in COVID-19. Beyond forming a physical barrier against pathogen invasion, RECs regulate bidirectional crosstalk with immune cells (including alveolar macrophages, dendritic cells, neutrophils, and lymphocytes) through multiple mechanisms, such as cytokine signaling, antigen presentation, PD-L1 checkpoint modulation, and renin-angiotensin-aldosterone system (RAAS) dysregulation. Under physiological conditions, these interactions promote viral clearance and epithelial repair; In contrast, dysregulation of such crosstalk leads to excessive inflammatory responses like cytokine storm and impaires tissue regeneration. Elucidating the molecular dynamics underlying REC-immune crosstalk is crucial for gaining insights into the development of targeted therapies (e.g., modulating cytokine signaling, restoring RAAS balance) to mitigate the severity of COVID-19. This review summarized recent findings to clarify how REC-mediated immune crosstalk dictates antiviral responses and pathological outcomes, thereby providing a theoretical basis for optimizing therapeutic strategies that strengthen antiviral immunity while minimizing immunopathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.